Net Quantity, Serving Size, and Potency Accuracy on Gummy Supplement Labels: Closing the Gap Between Manufacturing and Compliance

Why Gummy Labels Break Down Differently Than Capsule or Tablet Labels

When FDA investigators or third-party auditors scrutinize a gummy supplement label, they are not just comparing text to a regulatory checklist. They are asking a more demanding question: does what is printed on this label accurately reflect what is in the bottle, piece by piece, batch by batch? For capsules and tablets, that question is difficult enough. For gummy products, it is substantially harder because the format itself introduces variability that solid-dose forms do not.

Gummy supplements are produced through a cooking and depositing process — whether you run a mogul system with starch trays, a cold-deposit line, or a continuous belt depositor — that creates piece-weight variation as a function of temperature, viscosity, pump calibration, and die wear. After demolding, gummies shed moisture during conditioning and can gain or lose additional moisture depending on packaging, coating, and storage conditions. A gummy piece that weighed 3.2 grams at demolding may weigh 2.8 grams after conditioning and 2.6 grams six months into shelf life. If your label says each piece delivers 10 mg of zinc and you calculated that dose based on demolding weight, you may already be out of compliance before the product ships.

This is the core tension in gummy label compliance: the label is static, but the product is not. Closing that gap requires a quality system that ties label development directly to validated manufacturing data — not just to a formulation spreadsheet. Facility owners who treat labeling as a marketing function rather than a QA function consistently end up with products that cannot survive a finished-product certificate of analysis review, let alone an FDA audit.

Net Quantity of Contents: The Declaration FDA Checks First

Under 21 CFR Part 101.105, the net quantity of contents declaration must accurately represent the amount of food or supplement in the package. For gummies, this declaration is almost always expressed as a count — for example, "60 gummies" or "90 gummies" — though it may also include a weight statement depending on product type and label format. Both elements carry compliance risk specific to gummy manufacturing.

Count declarations sound simple until you account for the way gummy lines are filled. If you are filling bottles by count using an automated counter, you need validation data confirming that the counter is accurate across the fill speed range you actually use in production. Underfills discovered in the market are not just a customer service problem — they are a label misrepresentation under 21 CFR Part 101 and can trigger warning letters or voluntary recalls. Your batch records should document actual count verification for each lot, and your SOPs should define the acceptable tolerance and the response procedure when a count is out of range.

Weight-based net quantity statements introduce a second layer of risk. Because gummy piece weight changes with moisture loss during conditioning and post-packaging, a weight stated on the label must reflect the weight of the finished product as it will exist throughout its shelf life — not at any single point in your process. If you have not conducted moisture loss studies as part of your shelf-life validation, you are guessing at your net weight declaration, and FDA does not accept guesses. Your process validation program, required under 21 CFR Part 111 for dietary supplement manufacturers, must include data that supports the label claim through the end of the product's labeled shelf life.

• Verify counter accuracy at minimum and maximum production speeds and document the results in equipment qualification records.
• Conduct moisture loss profiling from demolding through end of shelf life, using water activity (Aw) and weight measurements at defined intervals.
• Set your fill quantity targets based on finished-product weight, not in-process weight, to ensure the label declaration remains accurate at time of consumption.
• Include net quantity verification as a line item in your batch release checklist, confirmed by QA — not just production.

Serving Size Declarations and the Dose Accuracy Problem in Gummy Formats

The serving size declaration on a gummy supplement label establishes how many pieces constitute one serving. That number must be consistent with the nutrient and ingredient amounts declared in the Supplement Facts panel. If your label says one serving is two gummies and each serving delivers 500 mg of vitamin C, then two gummies must actually deliver 500 mg of vitamin C — within the tolerance limits FDA applies. For dietary supplements, FDA applies the reference daily intake tolerances from 21 CFR Part 101.9, which for most nutrients allow a finished-product level no lower than 80 percent of the declared value.

In gummy manufacturing, the gap between the declared amount and the actual delivered amount widens for several reasons. First, active ingredients can degrade during the cooking process. Vitamins — particularly vitamin C, certain B vitamins, and botanicals with heat-sensitive constituents — lose potency when exposed to the high temperatures required to cook a gummy base. If your formulation was developed using room-temperature ingredient addition and your production line adds actives at 85°C, your potency assumptions are wrong before the product reaches the depositor.

Second, coating processes used to prevent gummy-to-gummy sticking — whether beeswax, carnauba wax, oil, or sugar sanding — add mass to the finished piece without adding active ingredient. If your potency per piece was calculated based on uncoated gummy weight and you coat the product after the fact, the mass denominator changes but the active ingredient does not, diluting the concentration per gram. This is rarely a compliance problem on its own, but it becomes one if your QC testing does not account for the coated piece weight when calculating per-serving potency.

Third, ingredient distribution across individual gummy pieces is not perfectly uniform. Gelatin- and pectin-based matrices can segregate certain active ingredients — particularly high-density minerals — during the cooking and depositing process. A finished batch may test at exactly the labeled potency in a composite sample while individual pieces vary widely above and below that mean. Under 21 CFR Part 111.75, you are required to test a representative sample of finished product for each dietary ingredient for which a claim is made. If your compositing method masks piece-to-piece variation, you may be releasing product that individual consumers find underdosed or overdosed.

• Conduct cooking-process degradation studies for each heat-sensitive active during formula development. Build an overage into your formulation to account for processing losses, and document the overage justification in your master manufacturing record (MMR).
• Recalculate potency per piece after coating and confirm that finished-product testing reflects coated piece weight.
• Use statistically valid sampling plans that test individual pieces as well as composites to detect within-batch distribution failures before release.
• Review finished-product COA results batch over batch for trend drift — if potency is consistently landing at 82 percent of label claim, your overage or process controls need adjustment before you fall below the 80 percent floor.

Supplement Facts Panel Accuracy: What FDA Investigators Examine Line by Line

The Supplement Facts panel is the most heavily scrutinized element of any dietary supplement label. Under 21 CFR Part 101.36, every component of the panel — serving size, servings per container, declared nutrients and dietary ingredients, percent daily values, and the other ingredients list — must meet specific formatting and accuracy requirements. For gummy products, several of these requirements have practical implications that generic label guides do not address.

Serving size must be expressed in a unit consumers can use — for gummies, that is typically a piece count. If your serving size is "2 gummies" but the gummies vary in size across flavors or SKUs, each variation needs its own serving size validation. A raspberry gummy and a lemon gummy in the same line that deposit at slightly different weights due to viscosity differences may deliver different potency per serving even if the formulation is nominally identical. Your QA program needs to treat each flavor or format variant as a separate product from a label accuracy standpoint.

The other ingredients list must accurately reflect every ingredient in the finished product in descending order of predominance by weight. For gummies, this list typically includes the base ingredients — gelatin or pectin, sugar, corn syrup or alternative sweetener, water — plus colorants, flavorings, acidulants such as citric or malic acid, and any functional coatings. If your coating vendor changes a component of the wax blend and your quality agreement does not require notification, you may be distributing product with an inaccurate other ingredients list without knowing it. This is a label violation and a supplier qualification failure simultaneously.

Allergen declarations on gummy labels require particular attention because gelatin is derived from animal sources — typically porcine or bovine — and certain gummy coatings or flavorings can contain tree nuts, soy, or dairy. While gelatin itself is not one of the nine major allergens under the Food Allergen Labeling and Consumer Protection Act, your facility's allergen control program must still document all potential cross-contact risks. If you produce pectin-based vegan gummies on the same line as gelatin-based gummies, your changeover SOP and allergen cleaning validation must support the allergen claims on both products' labels.

• Validate Supplement Facts accuracy by testing finished product from three or more consecutive batches at launch, then annually or whenever a formula or process change occurs.
• Treat each flavor variant as a distinct label accuracy risk and maintain separate potency testing records for each SKU.
• Require ingredient change notification from all coating, flavoring, and coloring suppliers in your quality agreements, and trigger a label review whenever a notification is received.
• Conduct allergen cross-contact risk assessments at the formula level and document them in your product risk profile, not just in your facility allergen plan.
• Audit your other ingredients list against your current MMR and current supplier specifications annually. Formulations drift over time, and the label must reflect the current product.

Building a Label Lifecycle Management System That Keeps Gummy Products in Compliance

The most common reason gummy supplement labels fall out of compliance is not ignorance of the regulations — it is the absence of a systematic process for keeping labels connected to manufacturing reality over time. A label that was accurate at product launch can become inaccurate when a supplier is changed, a process parameter is adjusted, a packaging format is modified, or a new flavor is added to the line. Without a formal change control process that includes a label impact assessment at every trigger point, these gaps accumulate silently until an FDA inspection or a market complaint makes them visible.

Under 21 CFR Part 111, change control is a required element of your quality system. Your change control SOP should explicitly include label review as a mandatory step for any change that affects ingredient identity, quantity, weight, serving size, allergen profile, or product format. QA sign-off on the label impact assessment should be required before any change goes into production. This is not a bureaucratic formality — it is the mechanism that keeps your label compliant as your product and process evolve.

Annual label audits are a best practice that many gummy manufacturers overlook because they feel burdensome. In practice, a structured annual review — comparing every panel element against current formulation records, current supplier specifications, current finished-product testing data, and current regulatory requirements — takes less time than responding to a warning letter and far less time than executing a recall. If you sell through Amazon, retailer portals like Whole Foods or Target, or have NSF certification, your label accuracy is already subject to third-party scrutiny at renewal. Building the internal audit practice aligns your compliance posture with the external pressure you will face regardless.

Finally, retain your label development documentation as part of your product history file. FDA investigators conducting inspections under 21 CFR Part 111 can and do request the data that supports label claims. If you cannot produce formulation records, overage justifications, finished-product potency testing, and process validation data that collectively demonstrate your label claims are accurate, you are vulnerable — even if your product is technically within specification. Documentation is not proof that you followed the rules. It is the only way to demonstrate it when someone asks.

• Implement a label impact assessment as a mandatory step in your change control workflow, with QA sign-off required before production release.
• Schedule annual label audits against current formulation, supplier, testing, and regulatory data. Assign a responsible owner and track completion in your quality system.
• Maintain a product history file for each SKU that includes all label versions, the data supporting each version, and a record of every change and its justification.
• Connect your label management process to your NSF, Amazon, and retailer renewal calendars so external audit deadlines drive internal review discipline.